{
    "organizations": [],
    "uuid": "6ed21b9e5cc403aa0e76613f96463f3b44a35c15",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-diffusion-pharma-qtrly-net-loss-pe/brief-diffusion-pharma-qtrly-net-loss-per-share-of-common-stock-0-27-idUSASC0A1K5",
    "ord_in_thread": 0,
    "title": "BRIEF-Diffusion Pharma Qtrly Net Loss Per Share Of Common Stock $0.27",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Diffusion Pharmaceuticals Inc:\n* DIFFUSION PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* DIFFUSION PHARMA - BELIEVE CASH & CASH EQUIVALENTS TO ENABLE CO TO FUND OPERATING EXPENSES, CAPITAL EXPENDITURE REQUIREMENTS THROUGH JUNE 2019\n* DIFFUSION PHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE OF COMMON STOCK $0.27 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:19:00.000+03:00",
    "crawled": "2018-05-11T12:57:59.037+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "diffusion",
        "pharmaceutical",
        "inc",
        "diffusion",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "diffusion",
        "pharma",
        "believe",
        "cash",
        "cash",
        "equivalent",
        "enable",
        "co",
        "fund",
        "operating",
        "expense",
        "capital",
        "expenditure",
        "requirement",
        "june",
        "diffusion",
        "pharmaceutical",
        "inc",
        "qtrly",
        "net",
        "loss",
        "per",
        "share",
        "common",
        "stock",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}